Characterization of Tissular T Follicular Helper Cells in IgG4-RD
TIFOLH4
2 other identifiers
interventional
30
1 country
1
Brief Summary
IgG4-related disease (IgG4-RD) is a recently identified rare disease characterized by inflammatory lesions with polyclonal lymphoplasmocytic infiltrate, with IgG4+ plasma cells predominance, and fibrosis in involved tissues. Despite a preferential involvement of exocrine organs, virtually all tissues can be affected by the disease. Corticosteroids are usually effective in this indication, but with poor tolerance and a high risk of relapse after decrease or withdrawal of this treatment. In this context, identification of new therapeutic targets is a major concern for these patients. Physiopathology of IgG4-RD remains actually unknown. In previous studies, it has been shown that T follicular Helper (Tfh) cells are expanded in the blood of these patients. Tfh cells have an important role in the formation of germinal centers (GCs), and ectopic GCs have been found in tissues of patients with IgG4-RD. Tfh cells have a major role in proliferation and differentiation of B cell compartment. In this context, this population could have an important contribution in the pathophysiology of IgG4-RD and could represent a therapeutic target in this disease. TIFOLH4 study intend to analyze tissue Tfh cells in patients with IgG4-RD at diagnosis. This study is an exploratory prospective multicentric study. Thirty patients with a suspected diagnosis of IgG4-RD, because of 1 or more suggestive organ involved, will be included in the study. A 50 mL blood sample and a biopsy, obtained in the same time of the diagnostic biopsy sample, will be obtained in this study. The results obtained in patients with a confirmed diagnosis of IgG4-RD (" IgG4-RD group ") will be compared to results of patients with another diagnosis (" control group "). Main objective of the study is to show by confocal microscopy an expansion of the number of Tfh cells (CD3+CD4+PD1+ cells) in tissue of IgG4-RD patients compared to controls. Secondary objectives include : tissue analysis of Tfh subsets (Tfh1, Tfh2 and Tfh17) ; tissue analysis of B regulatory cells, T regulatory cells, and T helper cells (Th1, Th2, Th17); correlation between tissue and circulating biomarkers; tissue proteomic analysis; and functional analysis of circulating Tfh cells after sorting of these cells and co-culture tests with autologous naive B cells. All these results will be compared between the " IgG4-RD group " and the " control group ". This study should clarify the role of these Tfh populations in IgG4-RD, identify diagnostic tissue and blood biomarkers, and identify therapeutic targets in these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 16, 2016
CompletedFirst Posted
Study publicly available on registry
August 19, 2016
CompletedStudy Start
First participant enrolled
February 14, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 8, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 8, 2021
CompletedOctober 30, 2023
October 1, 2023
3 years
August 16, 2016
October 27, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Location of TFH cells by immunofluorescence technical
Ratio of TFH cell on the number of total T lymphocytes by high power field in confocal microscopy in tissues of patients
36 months
Study Arms (1)
diagnosis of disease associated with IgG4
EXPERIMENTALpatients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
Interventions
One blood sample of 50 milliliter 24 hours after the inclusion
Eligibility Criteria
You may qualify if:
- Patient with a diagnosis of disease associated with IgG4
- Patient signed a consent
- Patient affiliated to the social security scheme
You may not qualify if:
- Patients with a corticosteroid therapy current or less than 3 months.
- Patients with an immunosuppressive treatment or being less than 3 months
- Patients with a biotherapy treatment by ongoing or less 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assistance Publique Hôpitaux de Marseille
Marseille, 13354, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 16, 2016
First Posted
August 19, 2016
Study Start
February 14, 2018
Primary Completion
February 8, 2021
Study Completion
February 8, 2021
Last Updated
October 30, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will not share